Collagen Peptide Supplements Increased Bone Density in Postmenopausal Women Over 12 Months

After 12 months, the collagen peptide group showed significant increases in bone mineral density compared to placebo at both measurement sites. Spine T-score changed by +0.1 in the collagen group vs. -0.03 in placebo (p=0.030). Femoral neck T-score changed by +0.09 vs. -0.01 (p=0.003). Bone formation marker P1NP increased significantly in the collagen group (p=0.007), while bone degradation marker CTX-1 increased significantly in the placebo group (p=0.011), indicating a favorable shift in the balance between bone formation and resorption.

Randomized, placebo-controlled, double-blinded study enrolling 131 postmenopausal women (102 completers, all 131 included in intention-to-treat analysis). Mean age 64.3 years, mean BMI 23.6 kg/m², with T-scores indicating osteopenia. Treatment group received 5 g/day of specific collagen peptides orally for 12 months. Primary endpoints were BMD changes at spine and femoral neck measured by DXA. Secondary endpoints included bone turnover markers P1NP and CTX-1.

Osteoporosis affects millions of postmenopausal women and leads to fractures that cause significant disability and mortality. If a simple daily collagen peptide supplement can increase bone density and improve bone markers, it could offer an accessible, low-risk complementary approach to osteoporosis prevention alongside calcium, vitamin D, and pharmaceutical treatments.

This is one of the more robust clinical trials showing collagen peptide effects on bone density, with a 12-month duration, placebo control, and DXA-measured endpoints. It adds to growing interest in collagen peptides beyond skin and joint applications. However, the study should be considered alongside the broader collagen supplement evidence base, including questions about industry funding influence noted in recent meta-analyses.

The study had a 22% dropout rate (131 enrolled, 102 completed), though intention-to-treat analysis was used. One author (Oesser) is associated with a collagen peptide manufacturer, raising potential conflict of interest. The T-score changes, while statistically significant, were modest. The study did not assess fracture risk reduction, which is the clinically meaningful endpoint. A single trial of this size should be replicated before drawing firm conclusions.